Announcements Trials
Browse Landscape

Phase

Phase NA 7Phase 4 4Phase 2 4Phase 3 3Phase 2/3 2

Status

Completed 3

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Breast 3

Conditions

Breast Neoplasms 3Vulvodynia 1Triple Negative Breast Neoplasms 1Neoplasm Metastasis 1Dyspareunia 1

Interventions

Cyclophosphamide 297Cisplatin 297Paclitaxel 258Radiotherapy 253Fluorouracil 234Carboplatin 234Docetaxel 231Doxorubicin 212Dexamethasone 164Gemcitabine 155Vincristine 143Etoposide 133Leucovorin 132Capecitabine 129Bevacizumab 129Prednisone 124Rituximab 118Methotrexate 117Cytarabine 108Filgrastim 99Trastuzumab 98Oxaliplatin 96pembrolizumab 81Pemetrexed 73Epirubicin 70Tamoxifen 69Drug Therapy 69Irinotecan 65Granulocyte Colony-Stimulating Factor 60Nivolumab 57

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 3 × Completed × Water × Clear all
NCT04799249 2024-08-01

PRESERVE 2

G1 Therapeutics, Inc.

Phase 3 Completed
194 enrolled
Breast

Breast Neoplasms, Neoplasm Metastasis, Triple Negative Breast Neoplasms

NCT01539317 2017-04-14

Therapy to Prevent Sexual Pain in Breast Cancer Survivors

OHSU Knight Cancer Institute

Phase 3 Completed
50 enrolled 9 charts
Breast

Breast Neoplasms, Dyspareunia, Vulvodynia

NCT01479244 2017-02-27

PRESENT

Galena Biopharma, Inc.

Phase 3 Completed
758 enrolled
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡